GW Pharma MS drug gets German approval
GW Pharmaceuticals has been given a lift after German authorities gave the thumbs up to its multiple sclerosis drug Sativex.
GW Pharmaceuticals has been given a lift after German authorities gave the thumbs up to its multiple sclerosis drug Sativex.
The firm, and its partner Almirall, claim Savitex can help treat moderate to severe spasticity in patients with MS.
The German drug regulators agree, although they say there is only "a minor added benefit".
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
"We are pleased by the positive decision of the G-BA, which recognises that Sativex has an important role to play in meeting the needs of patients with spasticity due to multiple sclerosism," said Farid Taha, Managing Director of Almirall Hermal GmbH.
"Whilst the G-BA has defined the benefit as minor, we believe that Sativex offers a substantial benefit to patients and we now look forward to the meeting with the pricing authorities as the next step in this process."
GW's stock was up 2.7% at 8:42.
BS
Sign up to Money Morning
Our team, led by award winning editors, is dedicated to delivering you the top news, analysis, and guides to help you manage your money, grow your investments and build wealth.
-
Saba Capital and Boaz Weinstein respond to investment trusts
As investment trust managers and industry experts accuse Saba of self-motivated opportunism, the hedge fund responds to specific "misleading claims" and sets out its stall
By Dan McEvoy Published
-
How to find top-quality companies with growing dividends
Ian Mortimer, portfolio manager of Guinness Global Equity Income Fund, shares where he would put his money for sustainable and growing dividends
By Ian Mortimer Published